Repka M X, Hardy R J, Phelps D L, Summers C G
Wilmer Ophthalmologic Institute, Johns Hopkins Hospital, Baltimore, MD 21287-9009.
Arch Ophthalmol. 1993 May;111(5):618-20. doi: 10.1001/archopht.1993.01090050052027.
The use of exogenous surfactant has led to a decrease in mortality of low-birth-weight infants. In some instances, use of this drug has also led to a reduction in neonatal morbidity, such as respiratory distress syndrome. This study was undertaken to determine whether prophylactic surfactant therapy has an effect on the incidence and severity of retinopathy of prematurity.
The authors reviewed the findings of sequential prospective ophthalmologic examinations performed in two neonatal intensive care units that participated in randomized trials of prophylactic exogenous mammalian surfactant.
There were 43 patients in the control group (no prophylactic surfactant) and 43 patients in the prophylactic surfactant group. These groups did not differ on the basis of birth weight, gestational age, race, or gender.
The incidence and severity of retinopathy of prematurity did not vary between the control and surfactant-treated infants. Only birth weight appeared to be significantly related to the incidence and severity of retinopathy of prematurity.
These results suggest that the widespread use of prophylactic surfactant therapy will not change the incidence of retinopathy of prematurity in extremely low-birth-weight infants. However, the absolute number of affected patients will likely increase because of the decrease in mortality of extremely low-birth-weight patients, the patients most at risk for retinopathy of prematurity.
外源性表面活性剂的使用已使低体重儿死亡率降低。在某些情况下,使用这种药物还能降低新生儿发病率,如呼吸窘迫综合征。本研究旨在确定预防性表面活性剂治疗对早产儿视网膜病变的发生率和严重程度是否有影响。
作者回顾了在两个参与预防性外源性哺乳动物表面活性剂随机试验的新生儿重症监护病房进行的系列前瞻性眼科检查结果。
对照组(未使用预防性表面活性剂)有43例患者,预防性表面活性剂组有43例患者。这些组在出生体重、胎龄、种族或性别方面无差异。
对照组和接受表面活性剂治疗的婴儿之间,早产儿视网膜病变的发生率和严重程度没有差异。只有出生体重似乎与早产儿视网膜病变的发生率和严重程度显著相关。
这些结果表明,预防性表面活性剂治疗的广泛使用不会改变极低体重儿早产儿视网膜病变的发生率。然而,由于极低体重患者(早产儿视网膜病变风险最高的患者)死亡率的降低,受影响患者的绝对数量可能会增加。